...
首页> 外文期刊>Angiology: the Journal of Vascular Diseases >Cardiovascular risk factors do not predict clinically defined restenosis after percutaneous transluminal angioplasty for lower limb ischemia.
【24h】

Cardiovascular risk factors do not predict clinically defined restenosis after percutaneous transluminal angioplasty for lower limb ischemia.

机译:心血管危险因素不能预测下肢缺血的经皮腔内血管成形术后的临床定义的再狭窄。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to evaluate risk factors predicting restenosis and primary patency after percutaneous transluminal angioplasty. Follow-up data (including cardiovascular risk factor scores according to SCVIR criteria, preinterventional and postinterventional clinical data and patient history) of all patients who underwent successful percutaneous transluminal angioplasty for lower limb ischemia were analyzed retrospectively and patients, relatives, or referring physicians underwent a telephone interview. Patients with incomplete follow-up data were examined by means of a clinical examination, including Doppler measurements and treadmill test. Additionally all angiograms were evaluated to calculate lesion length, number of treated lesions, lesion type (SCVIR score), and runoff. The outcome was categorized into four groups: early recurrence (< 1 month, group I), mean recurrence (1-6 months, group II), late recurrence (>6 months, group III), and no recurrence (group IV). According to common concepts group I was defined as early (thrombotic) reocclusion, group II as clinically defined restenosis, and group III as progression of atherosclerosis. One hundred thirty-seven patients underwent percutaneous transluminal angioplasty of 148 extremities. The groups differ significantly only with respect to a higher diabetes score for group I in comparison to group IV (p=0.002, Kruskal-Wallis test), and a worse runoff of group I compared with group IV (p =0.008). There was a trend toward a higher diabetes score for group II in comparison to group IV (p = 0.014). There were no differences with regard to hyperlipemia, hypertension, and tobacco use between patient groups. Mean primary patency was 436 days. Predictors for lower patency rates were diabetes mellitus (p<0.001), runoff (p=0.005), and number of treated lesions (p=0.007) in a stepwise, multiple regression analysis. Patients with clinically defined restenosis showed no specific risk factor profile in this study. Predictors for lower primary patency were diabetes mellitus, number of treated lesions, and runoff.
机译:这项研究的目的是评估经皮腔内血管成形术后预测再狭窄和原发通畅的危险因素。回顾性分析所有成功进行了下肢缺血性经皮腔内血管成形术的患者的随访数据(包括根据SCVIR标准的心血管危险因素评分,介入前和介入后临床数据以及患者病史),并对患者,亲属或转诊医师进行了随访。电话面试。随访数据不完整的患者通过临床检查进行检查,包括多普勒测量和跑步机测试。另外,评估所有血管造影照片以计算病变长度,治疗病变的数量,病变类型(SCVIR评分)和径流。结果分为四组:早期复发(<1个月,I组),平均复发(1-6个月,II组),晚期复发(> 6个月,III组)和无复发(IV组)。根据共同概念,第一组定义为早期(血栓形成)再闭塞,第二组定义为临床上的再狭窄,第三组定义为动脉粥样硬化的进展。 137例患者接受了148个四肢的经皮腔内血管成形术。各组之间的区别仅在于,与第IV组相比,I组的糖尿病评分较高(p = 0.002,Kruskal-Wallis检验),与I组相比,I组的径流更差(p = 0.008)。与IV组相比,II组有更高的糖尿病评分趋势(p = 0.014)。患者组之间在高脂血症,高血压和吸烟方面没有差异。平均主要通畅时间为436天。在逐步多元回归分析中,通畅率较低的预测指标是糖尿病(p <0.001),径流(p = 0.005)和已治疗病变的数量(p = 0.007)。具有临床定义的再狭窄的患者在该研究中未显示特定的危险因素。降低原发性通畅的预测因素是糖尿病,治疗的病灶数量和径流。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号